Ubiquitin-Specific Protease 10: A New Target in Tumor Immune Escape

Tumor immune escape is a major challenge in cancer treatment, and targeted immune escape therapy has become a key strategy for cancer treatment. As an important deubiquitinating enzyme, ubiquitin-specific protease 10 (USP10) participates in the process of tumor development by adjusting the balance between ubiquitination and deubiquitination of substrate proteins. Recently, USP10 has been shown to be closely related to tumor immune escape, where it serves to reduce the immunogenicity of tumor cells by stabilizing immune checkpoints and promotes tumor immune escape. In this review, we focus on the structural and functional characteristics of USP10 and elaborate on the biological function of USP10 in the occurrence and development of tumors, as well as its role in immune escape, including the regulation of immune checkpoints and the effect on immune cells in the immune microenvironment. It is possible to improve the efficacy of traditional cancer therapies by appropriately regulating the expression of USP10. The aim of this review is to provide a reference for further understanding the mechanism of tumor immune escape and the development of new tumor treatment methods.